SCHEMBL2908655

SCHEMBL2908655

CCOC(=O)c1cnc(SCC)nc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.56
SMN1; SMN2 Q16637 8/20 0.56
NPC1 O15118 7/20 0.56
ALDH1A1 P00352 5/20 0.56
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
POLB P06746 1/20 0.55
MAPT P10636 5/20 0.53
TSHR P16473 3/20 0.53
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
RECQL P46063 1/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7024255 0.87 ALDH1A1 (0.55) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL423187 0.86 MEN1 (0.64) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL29897636 0.86 MEN1 (0.64) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL7017546 0.85 ALDH1A1 (0.54) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL1991090 0.85 SMN1; SMN2 (0.76) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL20910144 0.82 SYK (0.55) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL15212266 0.81 ALDH1A1 (0.60) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL1669574 0.79 RAB9A (0.56) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL30996914 0.79 RAB9A (0.56) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1
SCHEMBL9591338 0.78 RGS12 (0.47) RAB9ASMN1; SMN2NPC1ALDH1A1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3660011-A1 BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR Janssen Pharmaceutica NV (BE) 2020-06-03 EP disclosed
US-9663497-B2 Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2017-05-30 US disclosed
US-20160340337-A1 BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR NOVASSAY S.A. (CH) 2016-11-24 US disclosed
US-9434715-B2 Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2016-09-06 US disclosed
US-9365548-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2016-06-14 US disclosed
US-20160159775-A1 BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2016-06-09 US disclosed
US-9278952-B2 Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2016-03-08 US disclosed
EP-2964229-A1 BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR Janssen Pharmaceutica, N.V. (BE) 2016-01-13 EP disclosed
US-20150148361-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2015-05-28 US disclosed
US-8962644-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA, NV (BE) 2015-02-24 US disclosed
US-20130072510-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (US) 2013-03-21 US disclosed
US-8343989-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2013-01-01 US disclosed
US-20100256373-A1 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR EDWARDS JAMES P 2010-10-07 US disclosed
EP-2007752-B1 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2010-08-18 EP disclosed
US-20090137608-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor EDWARDS JAMES P 2009-05-28 US disclosed
EP-2007752-A4 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2009-04-22 EP disclosed
US-7507737-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2009-03-24 US disclosed
EP-2007752-A2 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-31 EP disclosed
WO-2007117399-A2 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-18 WO disclosed
US-20070244126-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244126-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor HRH4, HRH2, HRH3 RAB9A 3687/4885SMN1; SMN2 4496/4885NPC1 3712/4885
US-20160340337-A1 BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR HRH4, HRH3, HRH2 RAB9A 2719/4885SMN1; SMN2 4441/4885NPC1 2570/4885
US-20160159775-A1 BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR HRH4, HRH3, HRH2 RAB9A 2719/4885SMN1; SMN2 4441/4885NPC1 2570/4885
US-20090137608-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor HRH4, HRH2, HRH3 RAB9A 3828/4885SMN1; SMN2 4580/4885NPC1 3835/4885
US-20100256373-A1 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR HRH4, HRH2, HRH3 RAB9A 3828/4885SMN1; SMN2 4580/4885NPC1 3835/4885
US-20150148361-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor HRH4, HRH2, HRH3 RAB9A 3687/4885SMN1; SMN2 4496/4885NPC1 3712/4885
US-20130072510-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor HRH4, HRH2, HRH3 RAB9A 3828/4885SMN1; SMN2 4580/4885NPC1 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.